Aims Women with gestational diabetes mellitus (GDM) have an increased risk of diabetes postpartum. We developed a score to predict the long-term risk of postpartum diabetes using clinical and anamnestic variables recorded during or shortly after delivery. Methods Data from 257 GDM women who were prospectively followed for diabetes outcome over 20 years of follow-up were used to develop and validate the risk score. Participants were divided into training and test sets. The risk score was calculated using Lasso Cox regression and divided into four risk categories, and its prediction performance was assessed in the test set. Results Postpartum diabetes developed in 110 women. The computed training set risk score of 5 9 body mass index in early pregnancy (per kg/m 2 ) ? 132 if GDM was treated with insulin (otherwise 0) ? 44 if the woman had a family history of diabetes (otherwise 0) -35 if the woman lactated (otherwise 0) had R 2 values of 0.23, 0.25, and 0.33 at 5, 10, and 15 years postpartum, respectively, and a C-Index of 0.75. Application of the risk score in the test set resulted in observed risk of postpartum diabetes at 5 years of 11 % for low risk scores B140, 29 % for scores 141-220, 64 % for scores 221-300, and 80 % for scores [300. Conclusions The derived risk score is easy to calculate, allows accurate prediction of GDM-related postpartum diabetes, and may thus be a useful prediction tool for clinicians and general practitioners.
Introduction
Gestational diabetes mellitus (GDM) affects 2-6 % of all pregnancies in industrialized countries [1] and is associated with an increased risk of diabetes postpartum [2, 3] . We have recently reported that lactation provides long-term protection against the development of postpartum diabetes in women with GDM, while insulin treatment during pregnancy and maternal obesity are associated with increased risk [4] . These findings indicate that further stratification of GDM women according to their actual postpartum diabetes risk is possible already shortly after delivery. We aimed to develop an easily applicable tool for diabetes risk stratification in GDM women, which may be helpful in clinical settings, particularly in the context of targeted and more efficient programs to detect and prevent the development of postpartum diabetes. For this purpose, we analyzed our data with a novel approach, using advanced statistical methods to obtain a risk score based on clinical and anamnestic variables that could improve longterm prediction of postpartum diabetes in women with GDM.
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Methods Participants
The prospective German GDM study followed women with GDM from delivery for up to 20 years to detect the development of postpartum diabetes. A detailed description of the study design has been previously reported [4] [5] [6] . In brief, a total of 304 patients with GDM were recruited between 1989 and 1999 across Germany and followed up until 2014. Patients were followed for the development of diabetes postpartum by means of an OGTT at 2 and 9 months; 2, 5, 8, 11, 15, and 19 years after pregnancy; or until the diagnosis of diabetes. OGTTs were performed by the patient physician. In addition, if women presented with symptoms of diabetes between follow-up visits, physicians took blood glucose measurements to test for clinical diabetes. Postpartum diabetes onset was defined according to American Diabetes Association criteria, which included unequivocal hyperglycemia with acute metabolic decompensation or the observation of a 2-h plasma glucose level [200 mg/dL after an oral glucose challenge, or a random blood glucose level [200 mg/dL if accompanied by unequivocal symptoms. Since 1997, a fasting blood glucose level[126 mg/dL on two occasions also was included as a diabetes diagnosis criteria in the study. Postpartum diabetes developed in 147 women (48.4 %). The median postpartum follow-up time from delivery was 8.1 years for women who did not develop diabetes.
Statistical analysis
To develop the risk score, we made use of the following variables: the mother's body mass index (BMI) in early pregnancy, GDM treatment (insulin or diet), family history of diabetes (yes vs. no), lactation duration (never, B3, or [3 months, coded as two dummy variables), and maternal age at delivery. These variables were collected by questionnaires or interviews and were chosen because they were easily ascertainable anamnestic information and had been previously associated with postpartum diabetes risk [4, 7] .
Of the 304 women with GDM, 257 were islet autoantibody negative and had complete data for the selected variables of interest; those 257 women were used to develop and validate the risk score (suppl. table S1). Of these women, 110 developed postpartum diabetes. In order to derive and test the prediction model in two independent data sets, the data were split into a training set (2/3; n = 171 women) and a test set (1/3; n = 86 women) using stratified random sampling. In the training set, the Lasso method for Cox regression [8] was used to reduce the final model to the most important variables to predict postpartum diabetes. We used a bootstrap approach to assess the robustness of the selection process with regard to the split into training and test sets. Therefore, we created 1000 different training sets of the same sample size (171 each) by sampling with replacement from the full data and assessed how often each risk factor was selected as a relevant predictor of diabetes development in those 1000 bootstrap data sets ( Table 1 ). The risk score was calculated based on the regression coefficients of the variables chosen for the final model, rounded to two decimal places, and multiplied with the factor 100.
The predictive performance of the risk score in the test set was assessed with three measures: R 2 at different times after delivery to assess the overall model performance [9] ; the C-Index, which is analogous to the area under the curve of logistic regression models, to assess discrimination [10] ; as well as the calibration slope, which should be around 1 for a well-calibrated score, and reflects the similarity of the absolute values of the predicted risk and the observed risk over the whole time period [11] .
The risk score was divided into four equally spaced intervals, and the predicted risk estimates of postpartum diabetes development in each category in the training set were compared with the respective observed diabetes rates in the test set.
All analyses were done using R version 3.0.2 [12] .
Results
In the training set, insulin treatment during pregnancy, family history of diabetes, BMI in early pregnancy, and lactation were selected as predictors of postpartum diabetes by the Lasso method ( Table 1) . As the same variables were also chosen in the majority of the 1000 bootstrap data sets, we were confident that our variable selection was robust to the split into training and test sets. The risk score was derived from their regression weights as follows: Risk score = 5 9 BMI in early pregnancy (per kg/ m 2 ) ? 132 if GDM was treated with insulin (otherwise ?0) ? 44 if the woman had a family history of diabetes (otherwise ?0) -35 if the woman lactated (otherwise -0). The risk score ranged from 54 to 380 in the training set (Fig. 1) . The risk score showed a prediction performance in the test set with R 2 values of 0.23, 0.26, and 0.33 at 5, 10, and 15 years, a stable C-Index of 0.75, 0.75, and 0.76, respectively, and a calibration slope of 1.13.
The risk score showed values of 54 to 380 in the training set and was divided into four equally spaced risk categories corresponding to values of B140 (low), 141-220 (medium), 221-300 (high), and [300 (very high risk). The predicted survival estimates in the training set at 5 years postpartum were 13, 31, 60, and 90 % for the mid-interval score of the four categories. These corresponded well with the observed risks in the test set of 11, 29, 64, and 80 %, respectively (Table 2) . Additionally, all observed risks in the test set fell within the confidence limits of the predicted risks (Fig. 2) .
Conclusions
In the present study, we developed a simple risk score to predict the long-term risk of postpartum diabetes in women with GDM. The risk score may be attractive for clinicians and general practitioners because it allows them to make long-term predictions on the risk of developing postpartum diabetes based on anamnestic variables that are generally recorded during pregnancy or shortly after delivery. We identified four meaningful risk categories, which may allow the scoring system to be applied in clinical settings. All of the variables included in the final risk score calculation-insulin treatment during pregnancy, family history of diabetes, BMI in early pregnancy, and lactation-have been shown to predict the risk of postpartum diabetes in earlier studies [7, [13] [14] [15] [16] , supporting the plausibility of this model.
The strengths of the present article lie in the unique prospective data and long-term follow-up used to generate the models. Further, we used an established variable selection method, assessed the stability of the variable selection through bootstrap, and tested the prediction performance of the risk score in an independent test set. The latter was necessary because we were unsuccessful in our attempts to include GDM cohorts from other study groups to validate the score.
Established measures of prediction performance, including the overall model fit, discrimination, and calibration, suggested the final risk score displayed good performance, comparable to risk scores used in other medical domains [17] . For example, the algorithm developed by Hippisley-Cox and Coupland to predict the risk of venous thromboembolism based on age, BMI, smoking status, history of several cardiovascular diseases, and recent hospital admission had R 2 values of 0.33 and 0.34 in women and men, respectively, and an area under the curve of 0.75 for both sexes. Furthermore, the observed rates of postpartum diabetes in the test set were very close to the predicted risks in the training set for each risk category, indicating high validity.
Other diabetes-related risk scores have been reported in the literature. Elevations in at least four out of six cardiometabolic risk factors (BMI, fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and systolic blood pressure) were found to determine a highrisk group for postpartum diabetes 10 years after delivery in 150 Australian GDM women, using a cluster-analysisbased approach [18] . However, data were not divided into training and test sets in this study, so that the prediction performance of the risk stratification could not be assessed, and overfitting might be an issue. In another study, a weighted genetic risk score based on 48 variants was found to slightly improve prediction of postpartum diabetes development within approximately 4 years after delivery in 395 Korean women with GDM history, if added to a complex model based on age, family history of diabetes, prepregnancy BMI, blood pressure, fasting glucose, and fasting insulin levels [15] . Unfortunately, our data did not contain metabolic or genetic measurements, which are useful for diabetes prediction in general [19] [20] [21] [22] . However, with a C-Index of 0.75 for diabetes development after 5 years, the prediction performance of our risk score was almost identical to that of the Korean study, where C-indices of 0.77 and 0.74 with and without genetic markers were observed, respectively. Furthermore, measuring metabolic and particularly genetic markers requires efforts in time and money, while our risk score has the advantage of only using variables that can easily be obtained shortly after delivery. The variables in our risk score are likely to reflect underlying glycemic parameters [23] , and two of them (BMI and insulin treatment) have already been suggested to be used for identification of high-risk groups suitable for targeted intervention measures [24] . Analyses of a large prospective data set suggested that, in addition to weight and family history of diabetes, a number of further easily obtainable factors such as waist circumference, hypertension, or short stature might be relevant predictors of type 2 diabetes [25] . However, these results were based on data of elderly people (aged 45-64 years) and may therefore not directly be transferable to women who recently had a GDM pregnancy, particularly as insulin treatment during pregnancy was found to be the most important predictor of diabetes development in these women.
The generalization of our findings to populations of different (i.e., non-Caucasian) ethnic backgrounds requires verification. Furthermore, the criteria for GDM diagnosis have changed since the time when our patients were recruited, and the cohort is likely to contain also cases which would now be diagnosed as diabetes with first onset during pregnancy rather than GDM according to the current World Health Organization guidelines [1] . Due to the missing blood glucose levels at GDM diagnosis, we were not able to reclassify women according to the current WHO criteria.
In conclusion, this risk score may be an important contribution to the prediction of GDM-related postpartum diabetes, allowing practitioners to easily estimate the diabetes risk in women with prior GDM to help tailor their follow-up examinations, and clinicians to identify high-risk women for targeted prevention studies. Author contributions MK analyzed the data and wrote the first and final drafts of the manuscript together with AB. AGZ designed the study, conceived the analysis, and critically revised the manuscript.
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